Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/121168
The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive patients receiving any front-line therapy in the context of a detailed prognostic evaluation, including assessment of IGHV, TP53, NOTCH1 and SF3B1 mutations. The median follow-up was 73 months (range, 2-202) from disease evaluation. The median treatment-free survival durations for patients achieving a complete response without or with minimal residual disease, a partial response and no response were 76, 40, 11 and 11 months, respectively (P<0.001). Multivariate analysis revealed that three variables had a significant impact on treatment-free survival: minimal residual disease (P<0.001), IGHV status (P<0.001) and β2-microglobulin levels (P=0.012). With regards to overall survival, factors predictive of an unfavorable outcome were minimal residual disease positivity (P=0.014), together with advanced age (P<0.001), unmutated IGHV status (P=0.001), TP53 mutations (P<0.001) and elevated levels of β2-microglobulin (P=0.003). In conclusion, for patients requiring front-line therapy, achievement of minimal residual disease negativity is associated with significantly prolonged treatment-free and overall survival irrespective of other prognostic markers or treatment administered.
Matèries (anglès)
Citació
Citació
SANTACRUZ, Rodrigo, VILLAMOR I CASAS, Neus, AYMERICH GREGORIO, Marta, MARTÍNEZ TRILLOS, Alejandra, LÓPEZ GONZÁLEZ, Cristina, NAVARRO LÓPEZ, Alba, ROZMAN, María, BEÀ BOBET, Sílvia m., ROYO MORENO, Cristina, CAZORLA, Maite, COLOMER PUJOL, Dolors, GINÉ SOCA, Eva, PINYOL, Magda, PUENTE, Xose s., LÓPEZ-OTIN, Carlos, CAMPO GÜERRI, Elias, LÓPEZ GUILLERMO, Armando, DELGADO, Julio (delgado gonzález). The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.. _Haematologica_. 2014. Vol. 99, núm. 5, pàgs. 873-880. [consulta: 21 de gener de 2026]. ISSN: 0390-6078. [Disponible a: https://hdl.handle.net/2445/121168]